Difference between revisions of "Ticagrelor (Brilinta)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
Line 4: | Line 4: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
− | =History of changes in FDA indication= | + | ==History of changes in FDA indication== |
'''Note that this agent does not have a hematology-specific indication at this time.''' | '''Note that this agent does not have a hematology-specific indication at this time.''' | ||
*7/20/2011: Initial FDA approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction). | *7/20/2011: Initial FDA approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction). | ||
*9/3/2015: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute Guide coronary syndrome (ACS) or a history of myocardial infarction (MI). | *9/3/2015: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute Guide coronary syndrome (ACS) or a history of myocardial infarction (MI). | ||
+ | |||
+ | ==Also known as== | ||
+ | *'''Brand names:''' Brilinta, Brilique, Ticalog | ||
[[Category:Drugs]] | [[Category:Drugs]] |
Revision as of 15:40, 6 August 2019
General information
Class/mechanism: Reversible cyclopentyl-triazolo-pyrimidine class inhibitor of the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets, inhibiting platelet activation and aggregation.
Route: PO
Extravasation: n/a
History of changes in FDA indication
Note that this agent does not have a hematology-specific indication at this time.
- 7/20/2011: Initial FDA approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).
- 9/3/2015: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute Guide coronary syndrome (ACS) or a history of myocardial infarction (MI).
Also known as
- Brand names: Brilinta, Brilique, Ticalog